Skip to main content

Table 2 Upgrade rate, adequacy of surgical lymph node biopsy, and rate of lymph node metastasis in patients diagnosed as ductal carcinoma in situ before operation

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

Upgrade ratio versus operation method
  BCS Mastectomy Total P value  
DCIS 194 255 449(65.8%) <0.01  
DCIS-IC 58 175 233(34.2%)  
Total 252 (37%) 430 (63%) 682  
Post-OP pathology and lymph node surgery
Post-OP pathology DCIS DCIS-IC Total P value  
Axillary surgery
ALN biopsy/dissection 397(58.2%)
over treatment
223(32.7%)
adequate treatment
620 0.01  
No axillary surgery 52(7.6%)
adequate treatment
10(1.5%)
under-treatment
62   
Total 449 233 682(100%)   
Pathology and lymph node metastasis distribution
  Pre-OP DCIS
N=682
Pure-DCIS
N=449
DCIS-IC
N=233
Pre-OP invasive cancer
N=2268
P value
No LN metastasis 92.4% (600/649) 99.2% (394/397) 79.4% (177/223) 61% (1385/2268) <0.01
LN metastasis 7.6% (49/649) 0.8% (3/397) 20.6% (46/223) 39% (883/2268)  
No axilla surgery N=33 N=52 N=10 N=0  
N1 0 1 ITC, 1micro-metastasis 80.4% (37/46) 68% (600/883)  
N2 0 0 15.2% (7/46) 21.9% (193/883)  
N3 0 1 4.3% (2/46) 10.2% (90/883)  
Breast MRI lymph node metastasis evaluation
  MRI predict LN metastasis MRI predict LN negative Total
Pathology LN metastasis 14 12 26
Pathology LN negative 80 280 360
Total 94 292 386
Sensitivity=14/26=53.8%
Specificity=280/360=77.8%
Positive predictive value (PPV)=14/94=14.9%
Negative predictive value (NPV)=280/292=95.9%
Accuracy= (14+280)/386 =76.2%
  1. DCIS ductal carcinoma in situ, DCIS-IC ductal carcinoma in situ with invasive component, BCS breast conserving surgery, ALN axillary lymph node, OP operation, LN lymph node, ITC isolated tumor cell